$MLAB

Sakys John sold $124K of MLAB

Sakys John (CFO) sold 1,223 shares of MESA LABORATORIES INC /CO/ (MLAB) at $101.27 ($0.12M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakys John
Published Jun 17, 2026, 4:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 4:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

This disclosure updates the insider trading record but does not, by itself, change company fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the scheduled nature and lack of additional catalysts suggest limited trading edge.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought, whether the company had concurrent news, or whether the sale size is part of a larger pre-set tranche.

Relevance 3/10Novelty 5/10Timing: filed 2026-06-17 (sale dated 2026-06-16)

Background

The article is an SEC Form 4 insider transaction for Mesa Laboratories (MLAB), reporting an officer sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

CFO Sakys John filed an SEC Form 4 open-market sale of 1,223 shares at $101.2670 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Likely minimal impact; any reaction should be small and short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a scheduled 10b5-1 sale by an officer, with no accompanying operational, financial, or regulatory catalyst disclosed in the text.

Market effects

No sector-level implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with private concerns; traders may still watch for follow-on selling or changes in insider behavior.

Key entities

  • MLAB

    Issuer of the SEC Form 4 insider transaction; CFO sale reported.

  • Sakys John

    CFO reporting an open-market sale of 1,223 shares under a 10b5-1 plan.

Related articles

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.